key: cord-0754157-s6jit82u
authors: Girardin, R.; Dupuis, A. l.; Payne, A. F.; Sullivan, T. J.; Strauss, D.; Parker, M. M.; McDonough, K.
title: Temporal Analysis of COVID-19 Convalescent Plasma Donations Reveals Significant Decrease in Neutralizing Capacity Over Time
date: 2020-10-06
journal: nan
DOI: 10.1101/2020.10.04.20206011
sha: 8eb2da8fd1d94dfbdf7d8c59f2ff01228a62c9bd
doc_id: 754157
cord_uid: s6jit82u

COVID-19 convalescent plasma (CCP) received approval for use under an Emergency Use Authorization by the FDA for treatment of seriously ill patients. Use of CCP units with a signal-to-cutoff ratio of [≥]12 using the Ortho VITROS SARS-CoV-2 IgG test (OVSARS2IgG) is authorized. Little is known about the relationship between this ratio and the neutralizing capacity of plasma/sera against genuine SARS-CoV-2 virus. We measured the neutralizing capacity of 981 samples from 196 CCP donors 7-119 days post initial donation (DPID). Neutralizing capacity was assessed for 50% (PRNT50) and 90% (PRNT90) reduction of infectious virus using the gold standard plaque reduction neutralization test (PRNT). Importantly, while 32.7%/79.5% (PRNT90/PRNT50) of donations met the FDA minimum titer of 1:80 initially, only 14.0%/48.8% (PRNT90/PRNT50) met this cut-off [≥]85 DPID. A subset of 91 donations were evaluated using the OVSARS2IgG and compared to PRNT titers for diagnostic accuracy. The correlation of OVSARS2IgG results to neutralizing capacity allowed extrapolation to CCP therapy efficacy results. CCP with OVSARS2IgG ratios in the therapeutically beneficial group had neutralizing titers of [≥]1:640 (PRNT50) and/or [≥]1:80 (PRNT90). This information provides a new basis for refining the recommended properties of CCP that is used to treat severe COVID-19.

capacity was assessed for 50% (PRNT50) and 90% (PRNT90) reduction of infectious virus using 23 the gold standard plaque reduction neutralization test (PRNT). Importantly, while 32.7%/79.5% 24 (PRNT90/PRNT50) of donations met the FDA minimum titer of 1:80 initially, only 14.0%/48.8% 25 (PRNT90/PRNT50) met this cut-off ≥85 DPID. A subset of 91 donations were evaluated using the 26

OVSARS2IgG and compared to PRNT titers for diagnostic accuracy. The correlation of 27

OVSARS2IgG results to neutralizing capacity allowed extrapolation to CCP therapy efficacy 28 results. CCP with OVSARS2IgG ratios in the therapeutically beneficial group had neutralizing 29 titers of ≥1:640 (PRNT50) and/or ≥1:80 (PRNT90). This information provides a new basis for 30 refining the recommended properties of CCP that is used to treat severe 32 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The emergence of COVID-19 disease, caused by infection with the SARS-CoV-2 virus, 34 has precipitated a global public health crisis. Treatment of COVID-19 primarily consists of 35 supportive care, although several experimental therapies are being tested in clinical trials. 36 Convalescent plasma has long been used as a therapeutic for viral infections when other 37 effective drugs or therapies are absent and has been used to treat SARS infections (1, 2). To 38 date, more than 84,000 patients in the United States have been transfused with COVID-19 39 convalescent plasma (CCP) (3). The efficacy of CCP has been difficult to establish, but it is 40 thought that CCP has an acceptable safety profile and may provide therapeutic benefit (4-8). 41

Protective correlates of immunity have not been definitively established for COVID -19, 42 but vaccine trials in non-human primates have shown correlation between neutralizing antibody 43 response and protection from SARS-CoV-2 challenge (9, 10). Thus, the potential therapeutic 44 benefit of CCP is thought to be dependent on the ability of antibodies present in the plasma to 45 neutralize SARS-CoV-2 and block infection. Neutralizing antibodies from recovered patients compete with angiotensin-converting enzyme 2 for binding of receptor binding domain 47 (RBD) on the trimeric spike protein of SARS-CoV-2 (11). Several serological assays have been 48 developed to measure the binding of antibodies in sera/plasma to a variety of SARS-CoV-2 49 spike antigens, including RBD, the S1 subunit of spike, and trimeric conformations of the spike 50 ectodomain (12, 13). An absolute neutralizing titer associated with therapeutically beneficial 51 CCP has been difficult to elucidate, as many larger published studies characterized none or few 52 of the CCP units for neutralizing titer with live SARS-CoV-2 virus (5, 7, 8) . Instead, serological 53 assays that measure the titer of anti-RBD or anti-spike antibodies have served as surrogates, 54 and a lack of widely available standardized reagents and control sera make direct comparison 55 across labs difficult. Several different titers have been recommended after comparison of 56 customized ELISA-based assays to varied microneutralization assays that use SARS-CoV-2 57 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 6, 2020 . . https://doi.org/10.1101 /2020 virus, but the relationship between these assays and the neutralizing capacity of sera/plasma as 58 measured by the gold standard plaque reduction neutralization test (PRNT) is not always clear 59 (12) (13) (14) the OVSARS2IgG measures antibody binding to the SARS-CoV-2 S1 antigen. A single report 65 has shown concordance between OVSARS2IgG ratios and pseudovirus neutralization, but this 66 test has not been compared to PRNT using genuine SARS-CoV-2 (17). 67

Symptom severity has been reported to positively correlate with neutralizing capacity 68 convalescent COVID-19 patients, as does male gender and age (18, 19) . It has been suggested 69 that these criteria can be used to select the CCP donors most likely to contribute CCP with high 70 neutralizing capacity. However, a specific optimal window post symptom resolution for CCP 71 collection has not been defined (18). There is debate about the stability of neutralizing antibody 72 responses in recovered COVID-19 patients, with conflicting results from different studies. Prior 73 studies lacked serial specimens from the same individual, completed analyses on a small 74 number of serial specimens within a limited time frame, or did not assess neutralizing capacity 75 of paired specimens (14, [19] [20] [21] . There is great interest in understanding the durability of 76 neutralizing antibody responses in convalescent COVID-19 patients, as there is concern that 77 rapid decay in neutralizing capacity could result in susceptibility to re-infection with SARS-CoV-78 2. Additionally, significant decreases in the neutralizing antibody capacity of convalescent 79 COVID-19 patients would render time post symptom resolution a critical factor in CCP donor 80 selection. 81 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 6, 2020. . https://doi.org/10. 1101 /2020 The goals of this study are to characterize the neutralizing capacity of serial donations of 82 CCP using PRNT with genuine SARS-CoV-2, to evaluate the CCP-qualifying criteria of the 83

OVSARS2IgG test at different levels of neutralizing capacity, and to correlate PRNT titer and 84

OVSARS2IgG ratios to data on the therapeutic efficacy of CCP compiled by the Mayo Clinic/US 85 EAP COVID-19 Plasma Consortium (US-EAP-CPC). 86 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 6, 2020. . https://doi.org/10.1101/2020.10.04.20206011 doi: medRxiv preprint

The durability of the neutralizing capacity of CCP donors 88

Of the 981 specimens analyzed ranging up to 119 DPID, 61.1% were contributed by 89 males, 38.4% were contributed by females, and 0.5% were contributed by individuals that did 90 not specify gender. Specimens contributed by males had significantly greater mean neutralizing 91 capacities (P value <0.0001) than those contributed by females. The mean age of the study 92 population was 48 years. Age was weakly, positively correlated with neutralizing titer (PRNT50 93 Spearman r 0.2129, P value <0.0001; PRNT90 Spearman r 0.1988, P value <0.0001). 94

Neutralizing antibodies were not detected in 1.3% of CCP tested at the minimum dilution (1:20) 95 screened in this study. As a population, 25.8% (PRNT90) to 73.0% (PRNT50) of donations had a 96 PRNT titer of ≥1:80. Comparatively, 9.5% (PRNT90) to 51.4% (PRNT50) of all donations had a 97 PRNT titer of ≥1:160. 98

Neutralizing capacities of donations were compared in two-week intervals at the PRNT50 99 (Table 1 ) and PRNT90 levels (Supplemental Table 1 ). The proportion of specimens that meet the 100 FDA minimal 1:80 and recommended 1:160 cut-offs decreased over time at both levels of 101 neutralization. A significant proportion (23.4%) of donations decreased ≥4-fold in PRNT50 titer, 102 while fewer (8.5%) had a decreased PRNT90 titer versus their initial draw (Supplemental Table 2  103 and 3). Mean PRNT50 neutralizing titers decreased significantly over time (P <0.0001) ( Figure  104 1A and B). The most significant decreases in PRNT50 titer occurred at ≥43 DPID, suggesting a 105 6-week window, likely corresponding to 3 -9 weeks post symptom onset, is optimal for 106 maximizing collection of high titer CCP. While the decrease in PRNT90 neutralizing titers was not 107 statistically significant (P= 0.0661) (Supplemental Figure 1A and B), all donors with titers ≥1:320 108 experienced decreases in PRNT90 titer by their final draw (Supplemental Figure 1B) . While 9.2% 109 (18/196) of CCP donors converted from positive to negative for neutralizing activity at the 110 PRNT90 level, none of the donors converted from positive to negative for neutralizing activity at 111 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 6, 2020. neutralizing capacity also had decreases in OVSARS2IgG ratios, the difference was not 121 statistically significant ( Figure 1C ). Sera with less than FDA mandated OVSARS2IgG ratio (<12) 122 had significantly lower PRNT50 and PRNT90 titers than sera with a ratio ≥12 (Figure 2A and D) . 123

Next, the distribution of PRNT titers was analyzed according to the OVSARS2IgG ratio ranges 124 used by the Mayo Clinic/US-EAP-CPC in a recent report on the efficacy of CCP (5). The 125 PRNT50 and PRNT90 titers of sera with an OVSARS2IgG ratio >18.45 were significantly higher 126 than those with ratios <4.62 or 4.62-18.45 ( Figure 2B and E). The samples analyzed include an 127 approximate representation of the distribution of neutralizing titers of the larger study population, 128 but performance characteristics could be altered if a greater proportion of specimens with very 129 high or very low neutralizing titers were assayed instead. 130

The accuracy of the OVSARS2IgG test to qualify high titer CCP was compared to the 131 reference standard PRNT at both levels of neutralizing capacity. The FDA-established 132

OVSARS2IgG ratio of ≥12 and the Mayo Clinic/US-EAP-CPC derived ratio of >18.45 were used 133 in the performance assessment. The ability of the OVSARS2IgG test to correctly identify sera 134 with any neutralizing capacity (inverse of the neutralizing titer (NT) NT≥20), or those with titers 135 at the FDA recommended levels (NT≥80 or NT≥160) at the PRNT50 (Table 2 ) and PRNT90 136 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 6, 2020. . https://doi.org/10.1101/2020.10.04.20206011 doi: medRxiv preprint levels was determined (Supplemental Table 4 ). The FDA cut-off of 12 resulted in 100% 137 specificity and positive predictive value for NT≥20 and NT≥80 at the PRNT50 level. Sensitivity 138 and negative predictive value improved when capturing specimens with NT≥80 or NT≥160 139 compared to NT≥20 at the PRNT50 level. 140 CCP with an OVSARS2IgG ratio >18.45 significantly correlates with improved outcomes 141 in patients transfused shortly after hospitalization (5). While our results support the use of an 142

OVSARS2IgG ratio ≥12 to exclude CCP with no neutralizing capacity from therapeutic use, we 143 determined whether an OVSARS2IgG ratio >18.45 provided additional discriminatory power. 144

Significantly, the >18.45 cut-off had improved specificity and positive predictive value for 145 specimens with NT≥160 (Table 2) . It also had better specificity and positive predictive value 146 than a cut-off of ≥12 for specimens with a NT≥20 or NT≥80 at the PRNT90 level (Supplemental 147 Table 4 ). The mean PRNT50 titer of the >18.45 group is 1:523.5 (mode >1:640), while the mean 148 PRNT90 titer is 1:190.4 (mode 1:80) ( Figure 2B and E) . Analysis of the distribution of neutralizing 149 titers compared to the OVSARS2IgG ratios and the ranges associated with efficacy by the Mayo 150

Clinic/US-EAP-CPC revealed that sera with the highest neutralizing capacity have 151

OVSARS2IgG ratios that are significantly higher than sera with low neutralizing capacity 152

(Figure 2 C and F). These direct comparisons between the neutralizing capacity of sera, their 153 corresponding OVSARS2IgG ratios, and the patient outcome data released by the Mayo 154

Clinic/US-EAP-CPC support updating recommendations for CCP use to specify that a PRNT90 155 titer ≥1:80 and/or a PRNT50 titer ≥1:640 qualify as high titer CCP. 156

The analysis presented herein clarifies the functional relationships between live SARS-157

CoV-2 virus neutralizing titers and the only current FDA approved surrogate neutralization test 158 for qualifying CCP. While an OVSARS2IgG test ratio ≥12 excluded all tested specimens with a 159 NT<20 at the PRNT50 level, this ratio does not exclude specimens with low neutralizing capacity 160 and uncertain therapeutic efficacy from being labeled high titer CCP. Rather, high titer CCP 161 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 6, 2020. . https://doi.org/10.1101/2020.10.04.20206011 doi: medRxiv preprint donations are better characterized by an OVSARS2IgG test ratio >18.45, which maximizes 162 specificity and positive predictive value at both levels of neutralizing capacity measured. This 163 recommendation is supported by our observation that CCP in a therapeutically beneficial 164 treatment group is most likely to have PRNT90 titer ≥1:80 and/or a PRNT50 titer ≥1:640. Along 165 with previously established guidelines for donor selection (18), consideration of time since 166 disease resolution will further refine donor selection to yield high titer CCP, particularly when 167 CCP donations cannot be tested for their neutralizing capacity using live SARS-CoV-2. 168 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 6, 2020. . https://doi.org/10.1101/2020.10.04.20206011 doi: medRxiv preprint

Specimens were collected from individuals who met all FDA donor eligibility 171 requirements (21CFR 630.10 and 21 CFR 630.15) and qualifications in accordance with the 172 guidelines of the New York Blood Center (NYBC). Donors were required to present 173 documentation of a positive SARS-CoV-2 PCR diagnostic test or positive serologic test after 174 recovery and to have been symptom free for at least two weeks. Donors contributed CCP/sera 175 at will, with a minimum of 7 days between serial contributions. Specimens were stored at -20°C 176 until tested. Testing at the Wadsworth Center was done under protocol 20-021 with approval 177 from the NYSDOH Institutional Review Board. 178

Participants were selected at random from a de-identified list of residual clinical 180 specimens submitted for anti-SARS-CoV-2 antibody testing at the Wadsworth Center 181

were retrospectively selected for study: 14-35d (n=45), 36-60d (n=27), 61-75d (n=55), and >75 183 (n=69). Sample selection and testing was blinded to clinical data including age, gender, and 184 SARS-CoV-2 antibody test results from the Wadsworth Center clinical assay. 185 PRNT analysis was conducted by mixing 100 ul of 200 PFUs of SARS-CoV-2, isolate 186 USA-WA1/2020 (BEI Resources, NR181 52281) with 100 ul of 2-fold serially diluted test sera 187 and incubated at 37°C in 5% CO2 for one hour. Confluent Vero E6 cells (C1008, ATCC CRL-188 1586) seeded in 6 well plates were inoculated with 100 ul of the virus:serum mixture and 189 adsorption proceeded for one hour at 37ºC in 5% CO2. A 0.6% agar overlay prepared in 190 maintenance medium (Eagle's Minimal Essential Medium, 2% heat-inactivated FBS, 100 µg/ml 191 Penicillin G, 100 U/ml Streptomycin) was added after adsorption and the assay was incubated 192 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 6, 2020. . https: //doi.org/10.1101 //doi.org/10. /2020 at 37ºC in 5% CO2. A second agar overlay with 0.2% Neutral red added was added two days 193 post infection. After an additional day of incubation, the number of plaques in each well were 194 recorded. The titer was reported as the inverse of the highest dilutions of sera providing 50% 195 (PRNT50) or 90% (PRNT90) viral plaque reduction relative to virus-only infection. Normal human 196 serum was used as a negative control and previously characterized COVID-19 patient sera was 197 used as a positive control in each assay. 198

A subset of ~10% of donor sera was selected for analysis using the Ortho VITROS 200 SARS-CoV-2 IgG test (OVSARS2IgG). Specimens with missing/indeterminate PRNT titers were 201 excluded from analysis. The subset was selected so it approximated the total study population 202 with regards to neutralization at/above the FDA minimal 1:80 titer at the PRNT50 level (total 203 study population = 73%, subset = 68.1%). Additionally, the subset included 11 matched pairs 204 with steady PRNT titers and 21 matched pairs with decreases in PRNT titers (late versus early 205 donation). Two selected donations had insufficient volume for testing, so were replaced with 206 specimens with equivalent titers selected at random from NYBC specimens subjected to PRNT. 207 DPID ranged from 0-114d for the subset. The OVSARS2IgG test was run on the Ortho VITROS 208 5600 instrument according to manufacturer's instructions and the signal-to-cutoff ratio was 209 automatically calculated by the system. The laboratorians completing the OVSARS2IgG were 210 blinded to clinical information on the specimens, including age, gender, SARS-CoV-2 antibody 211 test results from the Wadsworth Center clinical assay, PRNT results, and date of collection. 212

Correlation between age and neutralizing titer was assessed with a two-tailed 214

Spearman's r test. Statistical significance of correlations and comparisons between PRNT titers, 215 DPID, and OVSARS2IgG ratios were computed using the Kruskal-Wallis test with Dunn's 216 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 6, 2020. . https://doi.org/10.1101/2020.10.04.20206011 doi: medRxiv preprint correction for multiple comparisons when comparing three or more groups. The Mann-Whitney 217 test was applied when comparing two groups of a continuous variable, and the Kolmogorov-218

Smirov test was used when comparing two groups of a discrete variable. The sensitivity, 219 specificity, positive predictive value, and negative predictive value were calculated using the 220

Wilson-Brown method for calculating 95% confidence intervals. A two-sided Fisher's exact test 221 was used to assess significance of the effect sizes calculated. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 6, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 6, 2020 . . https://doi.org/10.1101 /2020 Wallis test with Dunn's correction for multiple comparisons was applied. Each of the two-week 292 time periods was compared to initial collection (0d) and statistically significant differences are 293 noted by the P value above the group. B. Initial (circles) and final (triangles) PRNT50 titers for all 294 donors. C. A subset of study participants were assessed using the OVSARS2IgG test and are 295 grouped by specimen pairs that had decreases in PRNT titers (Decrease) or those that were 296 constant (Constant). The Mann-Whitney test was applied; P values are indicated. A-B: n=91. C 297 n=91. 298 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 6, 2020. Dunn's correction for multiple comparisons was usedd to compare PRNT50 ≥20 to groups with 306 PRNT50 <20. P values are indicated. D. As in A, but for PRNT90 titers. E. As in B, but for PRNT90 307 titers. F. As in C, but for PRNT90 titers. n=91. 308 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 6, 2020. (27) 13.4% (11) 18.1% (13) 16.3% (7) 320 12.3% (24) 12.8% (28) 11.7% (17) 12.6% (14) 11.6% (13) 8.5% (7) 6.9% (5) 11.6% (5) 640 7.7% (15) 4.6% (10) 5.5% (8) 6.3% (7) 4.5% (5) 11.0% (9) 9.7% (7) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 6, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 6, 2020. . https://doi.org/10.1101/2020.10.04.20206011 doi: medRxiv preprint

Use of convalescent plasma therapy 235 in SARS patients in Hong Kong

Experience of using convalescent 237 plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital

Effectiveness of convalescent plasma therapy in 241 severe COVID-19 patients

Convalescent Plasma in 20,000 Hospitalized Patients

Effect of Convalescent 247 Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month 248 Experience. medRxiv

Compassionate use of convalescent 250 plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association 251 with IgG antibody levels in donated plasma

Patients with Convalescent Plasma Reveals a Signal of Significantly 254 Decreased Mortality

Rapid development of an inactivated vaccine 256 for SARS-CoV-2

Single-shot Ad26 vaccine 258 protects against SARS-CoV-2 in rhesus macaques

Human neutralizing antibodies elicited by SARS-260

CoV-2 infection

A 262 serological assay to detect SARS-CoV-2 seroconversion in humans

SARS-CoV-2 spike protein ectodomain and receptor binding domain IgG correlate with virus 266 neutralization

Neutralizing Antibody 268 Responses in COVID-19 Convalescent Sera

Convalescent plasma 270 treatment of severe COVID-19: a propensity score-matched control study

Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 275 Patients

Sex, age, and hospitalization 277 drive antibody responses in a COVID-19 convalescent plasma donor population